More importantly, blocking FAM111B via a small interfering RNA (siRNA) delivered by glypican-3 (GPC3)-targeted lipid nanoparticles (sGLNPs) successfully inhibited HCC progression and enhanced the lenvatinib effect in HCC treatment. This evidence concerns the gene FAM111B and hepatocellular carcinoma.